End-Stage Kidney Disease study: Metoprolol Succinate vs Carvedilol
Official title CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
ClinicalTrials.gov ID: NCT05931276
What this study is testing
What is Metoprolol Succinate?
Metoprolol Succinate is an investigational medicine, being studied as a potential treatment for end-stage kidney disease.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to find out if a dialyzable beta‑blocker (metoprolol succinate) leads to better heart outcomes than a non‑dialyzable beta‑blocker (carvedilol) in people on hemodialysis.
- Who it's for
- Adults receiving hemodialysis for end‑stage kidney disease.
- What's involved
- Participants will be randomly assigned to take either metoprolol succinate or carvedilol and will have regular check‑ups and tests during their dialysis visits to monitor heart health.
- Time commitment
- The trial lasts for the study period, with ongoing visits and assessments during routine dialysis sessions.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- On hemodialysis
- Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol
You likely can't join if
- Impaired decision-making capacity
- Patients not receiving carvedilol who have a history of asthma
- known hypersensitivity to any component of either drug
- Provider unwilling to sign a new medication order for a assigned by chance patient
- No surrogate consent will be allowed
The study team makes the final eligibility decision.
Where it is enrolling
- Long Beach, California, United States
- Aurora, Colorado, United States
- Gainesville, Florida, United States
- Chicago, Illinois, United States
- Iowa City, Iowa, United States
- Minneapolis, Minnesota, United States
- Omaha, Nebraska, United States
- Albuquerque, New Mexico, United States
- Durham, North Carolina, United States
- Philadelphia, Pennsylvania, United States
- Pittsburgh, Pennsylvania, United States
- Salt Lake City, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Long Beach, California, United States; Aurora, Colorado, United States; Gainesville, Florida, United States; Chicago, Illinois, United States; Iowa City, Iowa, United States; Minneapolis, Minnesota, United States and 6 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.